A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab

Ann Hematol. 2020 Nov;99(11):2699-2701. doi: 10.1007/s00277-020-04029-y. Epub 2020 Apr 21.

Authors

Yoshihito Horisawa¹, Tadakazu Kondo², Masakatsu Hishizawa¹, Kouhei Yamashita¹, Akifumi Takaori-Kondo¹

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
² Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan. tadakazu@kuhp.kyoto-u.ac.jp.

PMID: 32318778
DOI: 10.1007/s00277-020-04029-y

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors
ADP-ribosyl Cyclase 1 / immunology
Allografts
Antibodies, Monoclonal / administration & dosage
Antigens, Neoplasm / immunology
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Transplantation*
Bortezomib / administration & dosage
Combined Modality Therapy
Dexamethasone / administration & dosage
Humans
Lenalidomide / administration & dosage
Leukemia, Plasma Cell / drug therapy
Leukemia, Plasma Cell / therapy*
Male
Membrane Glycoproteins / antagonists & inhibitors
Membrane Glycoproteins / immunology
Middle Aged
Molecular Targeted Therapy*
Peripheral Blood Stem Cell Transplantation
Remission Induction
Salvage Therapy*
Transplantation Conditioning
Transplantation, Autologous

Substances

Antibodies, Monoclonal
Antigens, Neoplasm
Antineoplastic Agents, Immunological
Membrane Glycoproteins
daratumumab
Bortezomib
Dexamethasone
CD38 protein, human
ADP-ribosyl Cyclase 1
Lenalidomide